Dewaraja YK - Search Results

1

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, Youssef E, Regan D, Wilderman SJ, Roberson PL, Kaminski MS, Avram AM. Dewaraja YK, et al. J Nucl Med. 2014 Jul;55(7):1047-53. doi: 10.2967/jnumed.113.136044. Epub 2014 May 19. J Nucl Med. 2014. PMID: 24842891 Free PMC article. Clinical Trial.

2

I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.

Koral KF, Li J, Dewaraja Y, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL. Koral KF, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3004s-3009s. Clin Cancer Res. 1999. PMID: 10541335

3

Characterization of scatter and penetration using Monte Carlo simulation in 131I imaging.

Dewaraja YK, Ljungberg M, Koral KF. Dewaraja YK, et al. J Nucl Med. 2000 Jan;41(1):123-30. J Nucl Med. 2000. PMID: 10647615 Free PMC article.

4

Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.

Koral KF, Dewaraja Y, Li J, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL. Koral KF, et al. J Nucl Med. 2000 Sep;41(9):1579-86. J Nucl Med. 2000. PMID: 10994741 Free article. Clinical Trial.

5

Accuracy of 131I tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study.

Dewaraja YK, Ljungberg M, Koral KF. Dewaraja YK, et al. J Nucl Med. 2000 Oct;41(10):1760-7. J Nucl Med. 2000. PMID: 11038009 Free PMC article.

6

Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.

Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL. Koral KF, et al. Cancer Biother Radiopharm. 2000 Aug;15(4):347-55. doi: 10.1089/cbr.2000.15.347. Cancer Biother Radiopharm. 2000. PMID: 11041019

7

Monte Carlo evaluation of object shape effects in iodine-131 SPET tumor activity quantification.

Dewaraja YK, Ljungberg M, Koral KF. Dewaraja YK, et al. Eur J Nucl Med. 2001 Jul;28(7):900-6. doi: 10.1007/s002590100551. Eur J Nucl Med. 2001. PMID: 11504087 Free PMC article.

8

A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I using monte carlo simulation.

Ljungberg M, Sjögreen K, Liu X, Frey E, Dewaraja Y, Strand SE. Ljungberg M, et al. J Nucl Med. 2002 Aug;43(8):1101-9. J Nucl Med. 2002. PMID: 12163637 Free PMC article.

9

Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.

Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL. Koral KF, et al. J Nucl Med. 2003 Mar;44(3):457-64. J Nucl Med. 2003. PMID: 12621015 Free article.

10

Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.

Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Dewaraja YK, et al. J Nucl Med. 2005 May;46(5):840-9. J Nucl Med. 2005. PMID: 15872359 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters